Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-24-001220
Filing Date
2024-08-08
Accepted
2024-08-08 16:06:02
Documents
54
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q enzn-20240630x10q.htm   iXBRL 10-Q 738624
2 EX-31.1 enzn-20240630xex31d1.htm EX-31.1 12845
3 EX-32.1 enzn-20240630xex32d1.htm EX-32.1 6415
  Complete submission text file 0001410578-24-001220.txt   3242505

Data Files

Seq Description Document Type Size
4 EX-101.SCH enzn-20240630.xsd EX-101.SCH 31882
5 EX-101.CAL enzn-20240630_cal.xml EX-101.CAL 19364
6 EX-101.DEF enzn-20240630_def.xml EX-101.DEF 98756
7 EX-101.LAB enzn-20240630_lab.xml EX-101.LAB 224006
8 EX-101.PRE enzn-20240630_pre.xml EX-101.PRE 172768
57 EXTRACTED XBRL INSTANCE DOCUMENT enzn-20240630x10q_htm.xml XML 327799
Mailing Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016
Business Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016 732-980-4500
ENZON PHARMACEUTICALS, INC. (Filer) CIK: 0000727510 (see all company filings)

EIN.: 222372868 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-12957 | Film No.: 241188195
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)